Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Naptumomab estafenatox
Подписчиков: 0, рейтинг: 0
Monoclonal antibody | |
---|---|
Type | Fab fragment |
Source | Mouse |
Target | 5T4 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C3255H5025N855O1050S18 |
Molar mass | 73513.02 g·mol−1 |
NY (what is this?) (verify) |
Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma and renal cell carcinoma.
Mechanism of action
Chemically, it is a fusion protein consisting of the antigen-binding fragment (Fab) of a monoclonal antibody with the superantigen staphylococcal enterotoxin A (SEA/E-120, "estafenatox"). The Fab binds to 5T4, an antigen expressed by various tumor cells, and the superantigen induces an immune response by activating T lymphocytes.
See also
- Nacolomab tafenatox, a drug with a similar chemical structure and mechanism